Sponsored

Cynata (ASX: CYP) opens recruitment for phase 2 trial of CYP-001 in high-risk aGvHD

August 10, 2023 06:36 AM IST | By Sonal Goyal
 Cynata (ASX: CYP) opens recruitment for phase 2 trial of CYP-001 in high-risk aGvHD
Image source: Company website

Highlights

  • Cynata has opened recruitment in its Phase 2 clinical trial of CYP-001 in high-risk aGvHD.
  • Under the global trial, around 60 patients are targeted to be recruited.
  • The company expects to conclude recruitment for the trial by the end of 2024 and primary results in 2H25.

Cynata Therapeutics Limited (ASX: CYP) has opened the patient recruitment for Phase 2 clinical study of CYP-001 in patients with high-risk acute graft versus host disease (HR-aGvHD).

Cynata highlighted that the global trial would aim to enrol nearly 60 patients with HR-aGvHD. The recruited patients will be randomised to receive either steroids plus placebo or steroids plus CYP-001.

The first clinical centre to open for recruitment is Westmead Hospital, Sydney, Australia. The trial will be led by Professor David Gottlieb, who is a professor of Haematology at The University of Sydney. He is also the director of the blood transplant & cell therapies program at Westmead Hospital.

Cynata, a clinical-stage biotechnology company specialising in cell therapeutics, is managing and funding the trial.

 

Data source: Company update

The company expects the completion of enrolment by the end of 2024 and release the primary evaluation results in the second half of 2025. 

CYP shares traded at AU$0.145 at the time of writing on 10 August 2023. 


Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Limited, Company No. 12643132 (Kalkine Media, we or us) and is available for personal and non-commercial use only. Kalkine Media is an appointed representative of Kalkine Limited, who is authorized and regulated by the FCA (FRN: 579414). The non-personalised advice given by Kalkine Media through its Content does not in any way endorse or recommend individuals, investment products or services suitable for your personal financial situation. You should discuss your portfolios and the risk tolerance level appropriate for your personal financial situation, with a qualified financial planner and/or adviser. No liability is accepted by Kalkine Media or Kalkine Limited and/or any of its employees/officers, for any investment loss, or any other loss or detriment experienced by you for any investment decision, whether consequent to, or in any way related to this Content, the provision of which is a regulated activity. Kalkine Media does not intend to exclude any liability which is not permitted to be excluded under applicable law or regulation. Some of the Content on this website may be sponsored/non-sponsored, as applicable. However, on the date of publication of any such Content, none of the employees and/or associates of Kalkine Media hold positions in any of the stocks covered by Kalkine Media through its Content. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music/video that may be used in the Content are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music or video used in the Content unless stated otherwise. The images/music/video that may be used in the Content are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Top Penny Picks under 20 Cents to Fit Your Pocket! Get Exclusive Report on Penny Stocks For FREE Now.

Recent Articles

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.